Archive for the ‘Virus Killer’ Category

Containing Super-Flus – Controversy Brews Over Scientists' Creation Of Killer Viruses

Fouchier is attracting so much attention because he has created a new organism. And although it is tiny, if it escaped from his laboratory it would claim far more human lives than an exploding nuclear power plant.

The pathogen is a new mutation of the feared bird flu virus, H5N1. In nature, this virus, which kills one of every two people infected, has not yet been transmitted from humans to humans. So far, a relatively small number of people have caught the virus from poultry, and 336 people have died.

Scientific Wake-Up Call

For years, experts feared that the adaptable virus could soon mutate from being primarily a bird killer to a highly infectious threat to humans. But as the years passed and this did not happen, many hoped that it might not even be possible, and some of the fears subsided.

But now Fouchier's experiments have given the research community a wake-up call. The scientist performed only a few targeted manipulations on the genetic material of the ordinary H5N1 virus and, to make the virus even more dangerous, he repeatedly transmitted it from one laboratory animal to the next.

"In the end, the virus became airborne," the Dutch scientist explains. From then on Fouchier's ferrets, animals that most closely resemble humans when it comes to influenza, transmitted the virus to each other without direct contact, through tiny droplets of saliva and mucus.

Many scientists are particularly impressed by the fact that, at almost the same time, another research team also managed to produce a bird flu virus that could be transmitted via airborne respiratory droplets. To achieve this, virologist Yoshihiro Kawaoka of the University of Wisconsin combined the avian flu virus with the swine flu virus. The newly created superbug is highly infectious, however not particularly dangerous to the ferrets Kawaoka used in his experiments.

Articles Not Published

The scientific community anxiously anticipated learning about the details of the experiments. What exactly had Fouchier and Kawaoka done? How had Fouchier manipulated the bird flu virus? And, most of all, must the medical community now fear that the natural bird flu virus will develop in similar ways? Scientists hoped to find answers to these questions in findings that were to be published in the scientific magazines Nature and Science.

But the articles were not published. Officials from the NSABB had called the magazines' executive editors to prevent their publication. Because of the potential risk that the newly created bird flu viruses could be used as biological weapons, the organization asked the journals not to publish Kawaoka's and Fouchier's results, or at least not in their entirety.

This suddenly puts Fouchier at the center of an explosive controversy over biosecurity and academic freedom. Should scientists be allowed to create artificial viruses and bacteria, even if they are dangerous to human beings? What safety standards should be applied to their work? And should their controversial results be published, or is the risk too great that they will be misused as instructions to make biological weapons?

The debate has caused two opposing worlds to collide. The virologists, on the one side, suspect that the bio-terrorism watchdogs are being paranoid. The terrorism experts, on the other, feel that the scientists are simply naive.

'A Door Has Been Pushed Open'

The NSABB censorship came as a shock to most influenza researchers. "I've never seen anything like this," says Hans-Dieter Klenk, an influenza expert in the German city of Marburg. His colleague Stephan Ludwig, a virologist at the University of Munster in northwest Germany, sees the move as a threat to scientific freedom. "A door has been pushed open here that won't be so easy to close again," he says.

For many of the scientists, the idea that terrorists could misuse their viruses as weapons is simply absurd. "If I wanted to kill a lot of people, I would rent a truck, fill it with gasoline and fertilizer and blow it up," Fouchier says testily. Reinhard Burger, president of Berlin's Robert Koch Institute, Germany's federal institution for disease control and prevention, says: "I think the risk of misuse by terrorists is low."

Michael Osterholm, the most prominent member of the NSABB, completely disagrees. "I don't think it's a question of whether terrorists will use infectious pathogens to kill innocent civilians," he says. "It's just a question of when and how they do it."

High-Level Pressure

Osterholm can feel confident that he has support from the highest levels of the U.S. government. Last December, U.S. Secretary of State Hillary Clinton made a surprise appearance at the annual biological weapons convention in Geneva. Such a high-ranking U.S. official had not attended the event in decades.

Clinton spoke of "warning signals," even "evidence" that al-Qaeda was trying to recruit "brothers with degrees in microbiology or chemistry." "The nature of the problem is changing," she told the delegates. "A crude, but effective, terrorist weapon can be made by using a small sample of any number of widely available pathogens, inexpensive equipment and college-level chemistry and biology."

To buy some time in the face of so much opposition, 39 influenza researchers from around the world began a 60-day moratorium on all research related to controversial viruses at the end of January. "We realize that organizations and governments around the world need time to find the best solutions for opportunities and challenges that stem from the work," the scientists wrote in an open letter published in Nature.

But the scientists are deeply divided over what exactly these solutions should look like. While some would prefer not to make any changes, Richard Ebright, a molecular biologist at Rutgers University, proposes making research with artificially produced bird flu viruses subject to strict regulation, as is the case with pox viruses.

Past Experiments

But if such regulation is imposed, it will have to apply to more than avian flu viruses. Similarly controversial experiments have also been conducted with other pathogens:

-- In 2001, a mouse pox virus that was 100-percent fatal was accidentally created in an Australian laboratory. The genetic makeup of the killer virus was published.

-- In 2005, scientists at Stanford University calculated that a terrorist attack with botulinum toxin in milk could kill 568,000 people. The Bush administration tried in vain to prevent the paper from being published.

-- Nature recently published instructions on how to create the plague virus.

-- The influenza virus that caused the devastating Spanish Flu in 1918 has been completely recreated.

But security authorities only seem to be getting uneasy now, as they suddenly ask themselves a fundamental question: How great is the risk that such pathogens could escape from the laboratory, and that scientists would trigger precisely the devastating pandemic that they are in fact trying to prevent with their research?

Differing Safety Levels

Most virologists feel that the risks are justifiable. "We have set up a laboratory here that has three separate physical barriers," Fouchier insists. The core of the laboratory consists of wardrobe-sized boxes outfitted with glass windows, each containing four cages of ferrets.

Two pairs of black rubber gloves are poking into the boxes. "Before we take swabs from the animals or inject viruses into the nostrils, we put steel gloves on over the rubber gloves," says Fouchier. For security reasons, he is not even willing to provide the exact location of the laboratory.

The low pressure in the boxes provides additional protection, because it is intended to ensure that even in the event of a leak, no viruses will escape. In addition, everything that leaves the boxes is disinfected with acetic acid in a safety area.

"And if I did infect myself, we have isolation wards in the adjacent hospital," Fouchier explains. "It's practically impossible for one of my team members to accidentally take the virus along into the Rotterdam subway."

Nevertheless, not even Fouchier can deny that pathogens have escaped from highly secure laboratories. The "Russian flu" of 1977 may have been triggered by a lab virus. SARS, a respiratory disease, almost returned when laboratory workers became infected with the coronavirus during their work. A scientist in Chicago even died of SARS in 2009.

Hundreds of new virus laboratories have been established worldwide in recent years, and highly dangerous pathogens are used in a large share of these laboratories. "The risk of a virus being released accidentally is considerable," says critic Ebright.

That, says Ebright, is why future research involving bird flu viruses should only be done in laboratories with highest so-called biosafety level, BSL-4. Currently only the second-highest level, BSL-3, is required. During their experiments, Fouchier and Kawaoka only wore lab coats and breathing masks, not the "spacesuits" that virologists wear when they are working with pathogens like the Ebola virus.

'An Early Warning System'

Fouchier would prefer to take things a step further and send his pathogen to other labs around the world. "We are at the very beginning, and we need as many scientists and their ideas as possible, so that we can understand why this new virus is so contagious," he says.

In the end, whether the experiments with Fouchier's super-flu virus will continue or possibly be stopped altogether will probably not be determined by issues of safety, but by their potential benefits.

The situation is clear to Fouchier. Using his killer virus, he wants to find out which mutations in the genome are responsible for the extreme infection rates. "We'll know where to look in the future," says the virologist, who hopes that his research will allow him to develop an "early warning system for pandemics."

But this is precisely what others see as an illusion, noting that the monitoring of poultry and especially pigs, in which new viruses develop with particular frequency, is still far too incomplete. A colleague who knows Fouchier's work very well says that the experiments are "nothing more than a piece of the puzzle."

Intellpuke: You can read this article by Spiegel journalists Veronika Hackenbroch and Gerald Traufetter in context here: http://www.spiegel.de/international/spiegel/0,1518,815782,00.html
This article was translated from the German for Spiegel by Christopher Sultan.

Read more here:
Containing Super-Flus - Controversy Brews Over Scientists' Creation Of Killer Viruses

Nasal vaccine may soon toss cruise-ship crud overboard

Originally published February 18, 2012 at 8:04 PM | Page modified February 18, 2012 at 9:40 PM

VANCOUVER, B.C. — Bathing suit? Check.

Suntan lotion? Check.

Nose spray to keep diarrhea from ruining your cruise?

It's not on the check list yet, but scientists are closing in on a nasal vaccine that would protect against norovirus, the virulent bug that is the curse of cruise ships, cheerleading competitions — and any other venue that brings large numbers of people into proximity.

With an estimated 20 million infections a year nationwide, norovirus is the No. 1 cause of the intestinal crud people call stomach flu.

"This virus is very democratic," said Jan Vinje, of the U.S. Centers for Disease Control and Prevention (CDC). "It affects everyone."

If the research goes well, the vaccine could be available within five years, said Charles Arntzen, a molecular biologist at Arizona State University.

"We are going to have a vaccine," he said last week at the annual meeting of the American Association for the Advancement of Science. But it's not clear how effective a vaccine would be against a virus that evolves rapidly and comes in more than 30 varieties. And how many people will be willing to get vaccinated for a disease that's generally just a nuisance?

Sign me up, said Ellen Langan, of Ballard. Langan and her 16-year-old daughter, Ana Krafchick, were among more than 200 people who came down with norovirus after a cheerleading competition in Everett this month. Krafchick started throwing up the next evening and became so dehydrated she passed out and landed in the hospital.

Langan is convinced she picked up the infection while caring for her daughter. "I washed and disinfected my hands until they were raw and I still got it," she said.

While cruise ships and community outbreaks get most of the publicity, nearly 60 percent of norovirus cases occur in nursing homes, said the CDC's Vinje. Cruise ships account for 4 percent, and another 4 percent are linked to schools and school events. Children and adults are equally vulnerable.

Most victims recover after a day or two of misery, but more than 70,000 a year are hospitalized. CDC estimates the virus kills 800 people a year, most of them older than 65. The annual economic toll is about $2 billion in medical costs and lost productivity.

Though it seems like the virus came out of nowhere in the past few decades, it's been around for a long time, Vinje said. New tests make it easier to diagnose, so tracking has improved. The bug has also changed over time, with new strains emerging every few years.

Illnesses soar when the new strains are more virulent than the old ones. Cases may be spiking again this winter, Vinje said.

As Langan's experience shows, norovirus spreads quickly and can be harder to kill than the monster in the movie "Alien." Symptoms hit suddenly. Outbreaks often start when an infected person vomits in the corridor of a cruise ship, or, as in the case of the cheer competition, in a bathroom. Tiny particles fly through air and land on surfaces. Even the simple act of flushing the toilet after a bout of diarrhea or vomiting can suspend more droplets in the air.

The bug can also slip into the body via food, water or dirty hands. Once it does, as few as 18 virus particles are enough to do the trick, making norovirus the most infectious microbe known, Vinje said.

While many viruses are too fragile to survive long in the environment, noroviruses are encased in a BB-like shell that allows them to live for days or even months in some settings. One contaminated airplane cabin spread the disease to successive flight crews over several days.

Cruise ships have learned through hard experience that ordinary mopping isn't good enough. They now use bleach to disinfect every surface, including hand rails and poker chips, said Dr. Marcia Goldoft, an epidemiologist at the Washington Department of Health.

The first experimental vaccine worked well in a test on 100 people last year, Arntzen said. About two-thirds of those who got the vaccine were protected from infection with one particular strain of norovirus. But a commercial vaccine will need to cover multiple strains, he said. Preferably, it will also be long-lasting, though the bug mutates so quickly that a norovirus vaccine may have to be reformulated every year like the flu vaccine.

A nasal spray is better than a shot because it more directly targets the respiratory tract and gut where the virus concentrates.

Despite a potentially large market, the technical uncertainties have kept big pharmaceutical companies out of the race so far, Arntzen said. His lab at ASU is one of two in the United States working on the problem. The other is Ligocyte Pharmaceuticals, the biotech company that produced the vaccine tested last year.

Nursing homes and health-care workers would probably be the biggest customers, at least initially. But a vaccine might also find a market among cruise-ship clientele or frequent conference-goers.

"It would be more of an insurance policy than a primary health-care protection," Arntzen said.

In the meantime, since norovirus thumbs its nose at alcohol-based sanitizers, hand-washing remains your best line of personal defense.

But you have to do it right, Goldoft said. That means soap, warm water and vigorous scrubbing for as long as it takes to sing "Happy Birthday" — twice.

A recent study found 83 percent of people say they wash thoroughly, but only 17 percent do.

Sandi Doughton: 206-464-2491 or sdoughton@seattletimes.com

See the original post:
Nasal vaccine may soon toss cruise-ship crud overboard

Killer Virus Creation Spurs Debate

Should scientists be allowed to create extremely aggressive and highly infectious influenza viruses? Dutch virologists have done it and, in the process, triggered a fierce debate over the risks of bioterrorism and the potential release of deadly viruses.

The 17th floor of the Erasmus Medical Center in the Dutch city of Rotterdam certainly doesn't look like the kind of place that could pose a threat to global security. A disco ball hangs from the ceiling in the hallway in front of the elevators, and a bar with a golden beer tap stands in the corner of the conference room.

Everything in this 1960s high-rise building evokes the charm of student life, including the door to Room 17.73, which is covered with colorful stickers. But some view the scientist who sits behind that door as a threat to mankind.

Ron Fouchier, a giant of a man at more than two meters tall (6'6"), has dark circles under his eyes. His life has been stressful lately. "They want to paint me as a homicidal idiot," he says heatedly. He is referring, most of all, to a powerful institution from the United States, the National Science Advisory Board for Biosecurity (NSABB).

In his work Fouchier, a virologist, uses the methods of a branch of research that is as booming as it is controversial. Synthetic biology employs targeted manipulation through genetic engineering to construct new organisms. The 45-year-old's research has even set off alarm bells at the World Health Organization (WHO). This week, Fouchier will appear before an international panel of experts at the WHO to explain his experiments.

Universal Images Group/Getty Images

Fouchier is attracting so much attention because he has created a new organism. And although it is tiny, if it escaped from his laboratory it would claim far more human lives than an exploding nuclear power plant.

The pathogen is a new mutation of the feared bird flu virus, H5N1. In nature, this virus, which kills one of every two people infected, has not yet been transmitted from humans to humans. So far, a relatively small number of people have caught the virus from poultry, and 336 people have died.

Scientific Wake-Up Call

For years, experts feared that the adaptable virus could soon mutate from being primarily a bird killer to a highly infectious threat to humans. But as the years passed and this did not happen, many hoped that it might not even be possible, and some of the fears subsided.

But now Fouchier's experiments have given the research community a wake-up call. The scientist performed only a few targeted manipulations on the genetic material of the ordinary H5N1 virus and, to make the virus even more dangerous, he repeatedly transmitted it from one laboratory animal to the next.

"In the end, the virus became airborne," the Dutch scientist explains. From then on Fouchier's ferrets, animals that most closely resemble humans when it comes to influenza, transmitted the virus to each other without direct contact, through tiny droplets of saliva and mucus.

Many scientists are particularly impressed by the fact that, at almost the same time, another research team also managed to produce a bird flu virus that could be transmitted via airborne respiratory droplets. To achieve this, virologist Yoshihiro Kawaoka of the University of Wisconsin combined the avian flu virus with the swine flu virus. The newly created superbug is highly infectious, however not particularly dangerous to the ferrets Kawaoka used in his experiments.

Continue reading here:
Killer Virus Creation Spurs Debate

UVK (Ultra Virus Killer): Pt1 of 2 – Video

18-02-2012 17:06 This is part 1 of 2 of my UVK tutorial series. In this video I go into a little more detail on Ultra Virus Killer. This video covers Process Manager through UVK Tools. You will see there are a lot of tools to help remove viruses and repair your computer, and the great thing is, they're all in one place. Part 2 will finish off the tutorials with UVK System Repair Through Options. UVK: http://www.carifred.com Thank you for watching, have a great day !!

See more here:
UVK (Ultra Virus Killer): Pt1 of 2 - Video

3 Killer Criteria for Super Swing Trades – Weekend Wisdom

How do you find good stocks for great short-term trading opportunities? Do you hunt for value, growth or price momentum?

I look for all three, but with a twist that gives me an added "edge". I want to buy solid growth stocks after the market has "temporarily" and irrationally thrown them out with the bath water. If I am right that the selling insanity is temporary, I am also getting value that is about to resume a momentum price trajectory. The exaggerated reports of a great stock's death are often terrific "one shot, one kill" trading opportunities. Here are my essential screening gauntlet for "killer" swing trades with an edge: 1) Industry Dominator, Moat Optional
2) Earnings Machine with Institutional Sponsorship
3) Juicy Price Collapse that makes me say: "This stock is on sale!" The first criterion is pretty straight forward. I want to be looking at a well-run business with an established niche, if not industry domination. Obviously, a competitive moat is ideal. It's hard to get excited about price momentum if the company doesn't have other kinds of momentum going for it. The second criterion is all about growth. And when steady earnings momentum is confirmed by institutional investors accumulating and holding shares over long periods, you know you are in good company for higher prices in early to mid-stage growth. The third criterion is all about relative value. Sometimes good stocks get trashed for some of the following unwarranted reasons: Missed EPS or revenue target
Warned about a soft patch in business or economy
Made an acquisition the Street didn't like
New competitor is knocking on their niche
Concerns about the economy that cause a correction and sink all stocks with the market tide
Management change or a legal/regulatory/environmental battle cry from some assailant The assault could be any one of a dozen things that drive the price of a good company down 20% or more. In all cases, if you can confirm that criterion #1 and #2 are still intact, you may have just found a juicy bargain.
--------------------------------------------------------------------------------- Only Hours to Go for Hidden Bulls Saturday, February 18 is your last chance to target quick bull market swings that few are seeing. Time's running out to take advantage of the irrational behavior of other investors. The door must close to Zacks' new short-term investor group because if too many members were accepted, it would be harder for everyone to profit fully. Don't miss four powerful investment opportunities that are emerging... See them now >> ---------------------------------------------------------------------------------
3 Stocks That Screamed "Buy Me!"
1) CME Group ( CME )
The most dominant derivatives exchange in the world saw a slow drift lower in its shares for all of 2011. Falling from above $325 to support at $240 in the fall, the stock met strong resistance at its 200-day moving average in November at $280. And then things really got scary when one of its largest clearing members filed for bankruptcy on Halloween. The implosion of MF Global sent institutional investors running for the hills, and sent the stock to lows not seen since April of 2009. When I saw the stock trading at $225 in early January, I decided to take a closer look at the earnings picture. Estimates had definitely come down after the Corzine debacle, but the core business was intact, still dominant and still growing. Plus, the company was poised for potentially outstanding growth as trillions in the OTC interest rate derivatives business was destined to move to the exchange "mark-to-market" model. Sensing a fantastic opportunity, I bought March 260 calls for under $2.50. After CME's strong earnings report in February, the stock exploded from $240 to $290, handing my Tactical Trader subscribers at least a triple (200% gain) in those options, while some held on to see ten times their money!

2) Coinstar ( CSTR ) Remember when Netflix ( NFLX ) shot themselves in the foot by making their subscriber service more complicated and costly? Customers said "who needs this?" And investors punished the stock because they saw the company headed in all the wrong directions. Well a tiny little competitor for movie entertainment appeared to be headed down the same path after its October earnings report. Coinstar, owner of the Redbox DVD rental kiosks, raised their price by a whole 20 cents! The stock fell nearly 20% as investors thought it was another NFLX debacle. I said this was crazy! This price bump should only make CSTR earnings estimates go up. And everybody I knew who rented movies the Redbox way would gladly pay another 20 cents. Heck, most people I know would pay another buck and not think twice. Why? Because it's fun to go pick a flick that way - even if you are "streaming" video at home, which most consumers are not. I was so convinced about CSTR being a bargain, I told everyone to "buy it with both hands" under $45. The company was not only executing its core strategy, it was brewing the content distribution deal with Verizon for potential streaming opportunities. As you can see from the chart, CSTR caught a lot of bears by surprise on their last earnings report in early February. I made 24% on my shares.

3) Vertex Pharmaceuticals ( VRTX ) Vertex is not exactly a "dominator" in biotech when compared to Amgen or Celgene. But it did create something incredible last year that surprised lots of pharma experts and investors. They produced the first incredibly successful drug treatment for the hepatitis-C virus (HCV). Their drug Incivek topped sales of over $400 million in the third quarter of 2011, while pharma giant Merck could only do about $80 million in sales with their HCV treatment. Based on this success, the earnings estimates for Vertex soared to above $4 per share for 2012 with projected sales of over $2.5 billion. But the stock was already in a curious collapse before and after those results came out, getting cut in half from $52 to $26 in only two months. I decided to take a closer look at the catalysts. What I found was that the analyst community and large biotech investors were looking at all kinds of new competition for Incivek coming to market. The VRTX drug used an interferon cocktail regime with nasty side effects and lots of competitors were creating next-generation oral treatments that didn't need interferon. The biggest threat came from Gilead Sciences who had just paid $10 billion for Pharmasett to get their hands on that young biotech's HCV treatment. The problem was that none of these competitors would have their drugs ready for market until 2014. So with 170 million people worldwide exposed to HCV, and VRTX estimates not coming down, I thought that Incivek still would win in 2012. Plus, VRTX had a cystic fibrosis drug very close to FDA approval. On the very first day of the Tactical Trader service in early December, we opened the books by buying the VRTX April 30 calls for under $4. We just sold them for a 100% gain last week. Too bad we didn't keep them a little longer as the stock launched above my $40 price target Friday morning.

Catching Falling Knives, or Scooping Fallen Gems? There's an old adage in trading and investing that one can get really hurt trying to catch a falling knife. But if you do your homework, and you develop sound screening criteria that give you a very favorable risk/reward edge, you can bank sizable profits off the irrationality of other investors. I may not have the deep pocket and time horizon of a Warren Buffett, but my approach fully capitalizes on the idea to "be greedy when others are fearful."
No Need to Pursue These Profits on Your Own If you'd like some help, my private trading group has been re-opened until Saturday to new investors. Its purpose is to go long or short with stock, ETF, and options moves to catch small market swings that others rarely spot and ride them for substantial one to 12-week gains. The number of investors who share the moves from our Zacks Tactical Trader must be limited, and demand to get into the service was so intense that it had to be closed early when introduced last December. Now it's open to you again, but only until 11:59 pm Saturday, February 18. There will be no extensions so I strongly encourage you to look into it now. Click now for details about Tactical Trader >> Good Investing, Kevin Cook Kevin, a Senior Stock Strategist at Zacks, is a recognized authority in global markets. A former market-maker in the $4-trillion-dollar-a-day world of interbank trading, he developed the ability to track the movement of money, and trained his reflexes to take advantage of it. Today he directs the new Zacks Tactical Trader , providing commentary and recommendations.
 
CME GROUP INC ( CME ): Free Stock Analysis Report
 
COINSTAR INC ( CSTR ): Free Stock Analysis Report
 
VERTEX PHARM ( VRTX ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Continue reading here:
3 Killer Criteria for Super Swing Trades - Weekend Wisdom